GOLFIG increased progression-free survival in colorectal cancer patients
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Patients with advanced colorectal cancer are typically treated with combination chemotherapy with fluorouracil or the derivative product, capecitabine with or without levofolinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) given alone, or with the monoclonal antibodies bevacizumab, cetuximab or panitumumab.
"These combinations have been successful in inducing tumor regression, retarding disease progression and increasing overall survival. However, the average progression-free survival and overall survival are still no more than eight to 10 months and 20 to 22 months, respectively," said Pierpaolo Correale, M.D., Ph.D., an oncologist at the Siena University School of Medicine in Italy.
This study was started in 2005, before monoclonal antibodies were routinely used. Correale and colleagues added gemcitabine to FOLFOX followed by granulocyte-macrophage colony stimulating factor and low-dose aldesleukine (GOLFIG) to boost the immune system in an effort to fight cancer.
The researchers randomized 130 patients to receive GOLFIG or FOLFOX for a maximum of 12 cycles and then receive maintenance treatment until disease progression. The study was designed to follow the patients in both arms until death, but was ended early due to significantly better results seen with the GOLFIG regimen.
So far, the patients who received GOLFIG had a progression-free survival of 16.5 months compared with the 7.5 months recorded in those patients who received FOLFOX.
"Based on our experience and results to date, we believe that the GOLFIG regimen is superior to FOLFOX chemotherapy in terms of efficacy and comparable in terms of toxicity and cost," said Correale. "We were very surprised to find such a significant difference in terms of overall survival with this low number of patients."
The challenge for the future will be to compare GOLFIG regimen with regimens containing monoclonal antibodies, he said.
Provided by
American Association for Cancer Research
-
From lemons to lemonade: Reaction uses carbon dioxide to make carbon-based semiconductor,
32 comments
-
Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments,
3 comments
-
SpaceX private rocket blasts off for space station (Update),
42 comments
-
Climate scientists say they have solved riddle of rising sea,
30 comments
-
Research team claims to have found evidence Lake Cheko is impact crater for Tunguska Event,
18 comments
Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRC
-
Potential Breakthrough in Seizure Control
May 26, 2012
-
Popping/Cracked sternum.
May 25, 2012
-
Which Mental Illness Encompasses This Problem?
May 25, 2012
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
- More from Physics Forums - Medical Sciences
More news stories
Keep food safety in mind this memorial day weekend
(HealthDay) -- Picnics, parades and cookouts are as much a part of Memorial Day weekend as tributes to the United States' war veterans.
10 hours ago |
not rated yet |
0
Family history of Alzheimer's affects functional connectivity
(HealthDay) -- Cognitively normal individuals with a family history of late-onset Alzheimer's disease (AD) may display lower resting state functional connectivity in the default mode network (DMN) of the brain, ...
Medicine & Health / Alzheimer's disease & dementia
19 hours ago |
not rated yet |
0
Transvaginal mesh op restores pelvic organ prolapse at price
(HealthDay) -- Transvaginal mesh (TVM) procedures are effective for anatomical restoration of pelvic organ prolapse (POP), but patients report a worsening of sexual function following surgery, according to ...
19 hours ago |
not rated yet |
0
Travel to high altitudes tied to Crohn's, colitis flare-ups
(HealthDay) -- People with inflammatory bowel disease, which includes Crohn's disease and colitis, may be at increased risk for flare-ups when they fly or travel to high altitudes for skiing or mountain climbing, ...
Medicine & Health / Inflammatory disorders
20 hours ago |
not rated yet |
1
|
Weight struggles? Blame new neurons in your hypothalamus
New nerve cells formed in a select part of the brain could hold considerable sway over how much you eat and consequently weigh, new animal research by Johns Hopkins scientists suggests in a study published in the May issue ...
Medicine & Health / Neuroscience
May 21, 2012 |
5 / 5 (1) |
6
|
Scientist: Evolution debate will soon be history
(AP) -- Richard Leakey predicts skepticism over evolution will soon be history. Not that the avowed atheist has any doubts himself.
Dell tablet leak: 10.1-inch display, two-battery choice
(Phys.org) -- Headline after headline talks about vendors tablets in the wings as likely number-one contenders for the iPad. Such claims have justifiably been taken with a grain of salt, considering ...
SpotterRF debuts Radar Backpack Kit (w/ Video)
(Phys.org) -- SpotterRF has announced a special radar backpack kit designed to enhance situational awareness for soldiers on the ground. The company says its special radar is designed for warfighters as part ...
SpaceX capsule has 'new car' smell, astronauts say (Update)
SpaceX's Dragon cargo vessel smells like a new car, said astronauts at the International Space Station after opening the hatches Saturday following the spacecraft's landmark mission to the orbiting lab.
Thousands of shellfish found dead in Peru
Thousands of crustaceans were found dead off the coast of Lima following the mystery mass death of dolphins and pelicans, the Peruvian Navy said Friday.
Astronomers seize last chance in lifetime for Venus Transit
Astronomers are gearing for one the rarest events in the Solar System: an alignment of Earth, Venus and the Sun that will not be seen for another 105 years.